Shire Pays $57.5M To End ADHD Drug Marketing Probe

Law360, New York (February 1, 2013, 5:38 PM EST) -- Irish drugmaker Shire PLC said Friday that it has agreed to pay $57.5 million to resolve a U.S. investigation led by the U.S. Attorney's Office for the Eastern District of Pennsylvania into the sales and marketing of three drugs used to treat attention deficit hyperactivity disorder, including Adderall.

Shire said it had reached an agreement in principle to resolve the civil investigation first disclosed by the company in 2009. Shire said it had recorded a $57.5 million charge in the fourth quarter of 2012, comprised of...
To view the full article, register now.